You should not use Nipazol if you are allergic to it, or if you have taken disulfiram (Antabuse) within the past 2 weeks.
Do not drink alcohol or consume foods or medicines that contain propylene glycol while you are taking Nipazol and for at least 1 day after you stop taking it. You may have unpleasant side effects such as fast heartbeats, warmth or redness under your skin, tingly feeling, nausea, and vomiting.
Seizures and other nervous system abnormalities have been reported in patients treated with Nipazol. You should stop Nipazol immediately for any neurological symptoms such as seizures, headaches, visual changes, weakness, numbness, or tingling.
This medicine will not treat a viral infection such as the common cold or flu.
In animal studies (mice and rats), this medicine caused certain types of cancers or tumors. It is not known whether these effects would occur in people using this medicine. Ask your doctor about your risk.
Drugs That Induce CYP450 Enzymes
The simultaneous administration of drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of Nipazol, resulting in reduced plasma levels; impaired clearance of phenytoin has also been reported.
Nipazol is present in human milk at concentrations similar to maternal serum levels, and infant serum levels can be close to or comparable to infant therapeutic levels
Because of potential for tumorigenicity shown for Nipazol in mouse and rat studies, a decision should be made whether to discontinue nursing or to discontinue drug, taking into account importance of drug to mother; alternatively, a nursing mother may choose to pump and discard human milk for duration of Nipazol therapy, and for 24 hours after therapy ends and feed her infant stored human milk or formula
Nipazol is a nitroimidazole derivative bactericidal agent widely used in the treatment of many anaerobic and certain protozoan and parasitic infections. Nipazol has been linked to rare instances of acute, clinically apparent liver injury.
Michael Stewart, Reviewed by Dr Hannah Gronow | Last edited 21 Mar 2017 | Certified by The Information Standard
Swallow Nipazol tablets with plenty of water. Take them with a meal or a snack.
Do not drink alcohol while you are taking Nipazol, and for 48 hours after finishing your course of treatment.
Space your doses evenly throughout the day, and keep taking the medicine until the course is finished.
Nipazol may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
- upset stomach
- stomach cramps
- loss of appetite
- dry mouth
- sharp, unpleasant metallic taste
- furry tongue; mouth or tongue irritation
1. About metron >
Nipazol is an antibiotic.
It's used to treat skin infections, rosacea and mouth infections (including infected gums and dental abscesses). It's used in the treatment of conditions such as bacterial vaginosis and pelvic inflammatory disease.
It's also used to treat infected insect bites, skin ulcers, bed sores and wounds, and to treat and prevent bacterial and parasitic infections.
Nipazol is only available on prescription.
It comes as a tablet, gel, cream, a liquid you drink or a suppository which is a medicine that you push gently into your anus. It's also given by injection, but this is usually only done in hospital.
What is metron >
Nipazol is an antibiotic that fights bacteria.
Nipazol is used to treat bacterial infections of the vagina, stomach or intestines, liver, skin, joints, brain, heart, and respiratory tract. Metrogel (topical Nipazol) is also used to treat rosacea, a skin condition. Vaginal Nipazol gel is also used to treat bacterial infections of the vagina.
Nipazol will not treat a vaginal yeast infection.
There are no adequate and well controlled studies of FLAGYL in pregnant women. There are published data from case-control studies, cohort studies, and 2 meta-analyses that include more than 5000 pregnant women who used Nipazol during pregnancy. Many studies included first trimester exposures. One study showed an increased risk of cleft lip, with or without cleft palate, in infants exposed to Nipazol in-utero; however, these findings were not confirmed. In addition, more than ten randomized placebo-controlled clinical trials enrolled more than 5000 pregnant women to assess the use of antibiotic treatment (including Nipazol) for bacterial vaginosis on the incidence of preterm delivery. Most studies did not show an increased risk for congenital anomalies or other adverse fetal outcomes following Nipazol exposure during pregnancy. Three studies conducted to assess the risk of infant cancer following Nipazol exposure during pregnancy did not show an increased risk; however, the ability of these studies to detect such a signal was limited.
Nipazol crosses the placental barrier and its effects on the human fetal organogenesis are not known. Reproduction studies have been performed in rats, rabbits, and mice at doses similar to the maximum recommended human dose based on body surface area comparisons. There was no evidence of harm to the fetus due to Nipazol.